ClinicalTrials.gg
BiologicalDrug

Garadacimab clinical trials

Also written CSL312.

studies test it
9
open now
0
in phase 3
3
first study started
2018

How each study uses garadacimab is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Approvals

The first approval found in each region, with its record

United States
16 Jun 2025 · ANDEMBRY · BLA 761367 (FDA, Drugs@FDA)
European Union
10 Feb 2025 · Andembry · EMEA/H/C/006116 (EMA)

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

Garadacimab
7
Factor XIIa antagonist monoclonal antibody
3
Factor XIIa inhibitor monoclonal antibody
2

Development codes

CSL312
8

Studies by the year they started

9 studies that test it; most in 2020 (2)

Studies that test garadacimab, by start year
YearStudies
20181
20202
20212
20222
20231
20251

By phase

A phase 1/2 study counts in both.

Phase 1
3
Phase 2
3
Phase 3
3
Phase 4
1

What it is tested for

Each study’s main condition, where its own words name it, so a study counts once.

Who runs them

Industry 9 · Other 0

CSL Behring (9)

Studies

Open first, then newest update. How each study uses garadacimab is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 9

Codes

What other systems call garadacimab · ClinicalTrials.gg INT002144

  • MeSH (NLM) C000731822garadacimabOne source NLM
  • UNII (FDA) 32W6AJL0DYGARADACIMABConfirmed FDA, NLM
  • NCI Thesaurus C166633GaradacimabOne source FDA

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.